Alpha Tau Medical Ltd
NASDAQ:DRTS
Alpha Tau Medical Ltd
Research & Development
Alpha Tau Medical Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Alpha Tau Medical Ltd
NASDAQ:DRTS
|
Research & Development
-$27m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Nano-X Imaging Ltd
NASDAQ:NNOX
|
Research & Development
-$20.2m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
|
B
|
Brainsway Ltd
TASE:BWAY
|
Research & Development
-$9.1m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-7%
|
|
|
Inmode Ltd
NASDAQ:INMD
|
Research & Development
-$13.3m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Sisram Medical Ltd
HKEX:1696
|
Research & Development
-$15.9m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sofwave Medical Ltd
TASE:SOFW
|
Research & Development
-$10.4m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Alpha Tau Medical Ltd
Glance View
Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The firm has one subsidiary Healthcare Capital Corp.
See Also
What is Alpha Tau Medical Ltd's Research & Development?
Research & Development
-27m
USD
Based on the financial report for Dec 31, 2024, Alpha Tau Medical Ltd's Research & Development amounts to -27m USD.
What is Alpha Tau Medical Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-32%
Over the last year, the Research & Development growth was -2%. The average annual Research & Development growth rates for Alpha Tau Medical Ltd have been -33% over the past three years , -32% over the past five years .
